Rheumatoid arthritis, depression: How 2 conditions affect each other

Evan Walker
Evan Walker TheMediTary.Com |
portrait of older white woman with her eyes closed by a windowShare on Pinterest
Rheumatoid arthritis and depression: a two-way relationship? Here is what the most recent findings suggest. Image credit: Tatiana Maksimova/Getty Images
  • As of 2021, about 17.9 million people around the world were living with rheumatoid arthritis.
  • Past studies show that rheumatoid arthritis can negatively impact a person’s health by increasing their risk for several health complications, including depression.
  • Recent evidence suggests that some of these health issues may not only be complications of this condition, but may also help maintain the disease especially in people with difficult-to-treat rheumatoid arthritis.
  • Researchers have developed a new model based on their findings to help improve the treatment of difficult-to-treat rheumatoid arthritis cases.

As of 2021, about 17.9 million people globally were living with rheumatoid arthritis — an autoimmune type of arthritis that causes inflammation in the joints.

Past studies show that rheumatoid arthritis can negatively impact a person’s health by increasing their risk for irreversible joint damage, osteoporosis, heart disease, eye issues, sleeping problems, obesity, and mental health conditions like anxiety and depression.

Now, two new papers — a perspective paper published in the journal Nature Reviews Rheumatology, and a commentary in The Lancet Rheumatology — have concluded that some of these health issues, such as depression, may not only be complications of rheumatoid arthritis, but may also help maintain the disease especially in people with difficult-to-treat rheumatoid arthritis.

“For example, a patient with severe [rheumatoid arthritis] pain may become physically inactive, leading to obesity,” he detailed.

“Obesity generates low-grade systemic inflammation, which further worsens the [rheumatoid arthritis] trajectory. Similarly, failing multiple medications lowers mood and motivation, triggering depression; that depression then amplifies pain perception in the brain and lowers the patient’s ability to rigidly adhere to their treatment plan,” Nagy explained.

“Recognizing that these factors actively maintain the disease state is revolutionary because it means we can break the cycle by targeting the modifiable lifestyle factors directly, sometimes without even needing a new drug,” the researcher added.

“Currently, [rheumatoid arthritis] care is treated as a linear, ‘one-size-fits-all’ escalator,” he explained. “If a drug fails, the clinician automatically steps up to the next, stronger drug. Our model introduces a smart triage layer.“

“Instead of universally escalating medication when standard care under-performs, the clinician halts to perform a ‘structured multi-domain reassessment.’ We treat the patient’s unique condition like a puzzle, evaluating four specific zones: disease biology, clinical conditions (comorbidities), behavioral habits (adherence), and contextual realities (such as sleep or social support),” Nagy told us.

“Instead of just changing the prescription, our model might pivot a patient toward a multidisciplinary roadmap: engaging pain specialists, psychologists for mental well-being, or personalized nutrition and lifestyle coaching to address weight or smoking,” he continued. “It shifts medicine from rigidly treating a generic disease to flexibly treating an individual human being.”

Nagy said that finding new avenues for “difficult-to-treat” rheumatoid arthritis patients is vital because blindly escalating powerful immunomodulatory medications doesn’t work for everyone.

“Unnecessary drug escalation can expose patients to unwanted side effects and rising healthcare costs without actually relieving their symptoms,” he added. “We must understand the deeper, non-inflammatory drivers to alleviate this impactful clinical and socioeconomic burden.”

Share this Article